Stockreport

Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]

Trevi Therapeutics, Inc.  (TRVI) 
PDF TRVI's nalbuphine shows consistent efficacy in Phase 2 trials, but long-term effectiveness, side effects, and commercial potential remain uncertain. Competition from [Read more]